Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo, Palermo, Italy.
Ital J Pediatr. 2022 Aug 4;48(1):140. doi: 10.1186/s13052-022-01334-2.
Infantile hemangiomas may affect the quality of life (QoL) of patients and their family members, as anxiety and worry may commonly occur in parents, also linked to the social adversion they experience. We underline the beneficial impact of oral propranolol therapy on QoL of patients with infantile hemangiomas (IH) and of their relatives. A specific questionnaire measuring QoL was administered to parents of IH patients at beginning and end of a treatment with oral propranolol. Different aspects were investigated: site of the lesion, age of patients at starting therapy, length of treatment, occurrence of adverse effects and persistence/recurrence of the vascular anomaly. In all cases the questionnaire revealed a significant improvement of QoL, which was independent from all analyzed factors. It showed that oral propranolol administration in these patients combines optimal clinical results with relevant improvement of QoL, especially in cases of early management. The improvement of QoL seems unrelated to site of lesion, timing and duration of therapy, occurrence of drug-related adverse effects and persistence/recurrence of disease.
婴儿血管瘤可能会影响患者及其家庭成员的生活质量 (QoL)，因为父母通常会感到焦虑和担忧，这也与他们所经历的社会歧视有关。我们强调了口服普萘洛尔治疗对婴儿血管瘤 (IH) 患者及其亲属生活质量的有益影响。在开始口服普萘洛尔治疗前后，我们向 IH 患者的父母发放了一份专门测量生活质量的问卷。调查了以下几个方面：病变部位、开始治疗时患者的年龄、治疗时间、不良反应的发生以及血管畸形的持续/复发。在所有情况下，问卷均显示 QoL 显著改善，且与所有分析因素无关。这表明，在这些患者中使用口服普萘洛尔治疗可同时获得最佳的临床疗效和生活质量的显著改善，特别是在早期治疗的情况下。生活质量的改善似乎与病变部位、治疗的时机和持续时间、药物相关不良反应的发生以及疾病的持续/复发无关。
